Quantum Rocket or Bubble? RGTI’s Stunning Surge Explained—And How It Stacks Up to IonQ, D‑Wave, and QUBT

Rigetti Stock Skyrockets Amid Quantum Computing Boom – Bubble or Breakthrough?

  • Stock Surge: Rigetti (NASDAQ: RGTI) closed around $54.91 on Oct. 13, 2025 [1] (briefly hitting $55.23 intraday [2]). This marks roughly a +127% YTD jump by early Oct (far outperforming peers – IonQ and D-Wave were up ~+48% and +165% YTD by early Oct, respectively [3]).
  • Major Contracts: In late Sept 2025 Rigetti announced ~$5.7M in new orders for its 9‑qubit Novera systems and a $5.8M U.S. Air Force quantum networking contract [4]. These modest deals, along with unveiling its 36‑qubit “Cepheus‑1” processor, repeatedly fueled double-digit stock jumps [5].
  • Financials: Rigetti remains unprofitable. It booked $10.8M revenue in 2024 (net loss $201M) and only ~$1.8M in Q2 2025 (loss $39.7M) [6]. On the plus side, it has no debt and ~$571M cash (after a $350M stock raise) [7]. In short, sales are tiny and losses large, but the cash runway is strong.
  • Valuation vs. Analysts: At ~$55/share Rigetti’s market cap is ~$11–13B, implying an eye-watering price/sales ratio >1000× [8]. All covering analysts rate RGTI a Buy/Strong Buy [9], but most 12‑month targets (~$20–24) sit ~50% below today’s price [10] (notable exceptions: Benchmark’s $50, B. Riley’s $35).
  • Hype & Caution: Quantum computing is being hailed as “the most important technological race of our generation” (Bank of America) [11], fueling a retail frenzy. Rigetti’s stock has even been called a “meme stock” in this boom [12]. But critics warn it’s mostly speculation – CNBC’s Jim Cramer calls Rigetti “pure speculation” [13] and Barron’s notes its bubble may “keep inflating until tested by fundamentals” [14].

Rigetti Computing’s (RGTI) shares have surged into the mid-$50s in October 2025. In late Sept and early Oct, announcements of new contracts and technology milestones repeatedly sent the stock higher [15] [16]. Analysts note RGTI is trading on future promise more than current sales.

Rigetti Stock Performance

Rigetti’s stock has exploded higher in recent weeks. On Oct. 13, 2025, RGTI spiked about +25% intraday to a record ~$55.23 (closing $54.91) [17]. This burst was largely in response to news that JPMorgan is investing $10 billion in “frontier” tech including quantum computing [18]. As Insider Monkey reported, “Rigetti Computing surged to a new record high… as investors snapped up shares in industries targeted by JPMorgan’s $1.5 trillion investment plan” [19]. D-Wave and other quantum stocks also rallied on this news [20]. By Oct. 14 RGTI closed around $56 and in early Oct it was trading in the mid-$50s, far above the ~$20 range of mid-September. Year-to-date, RGTI is up roughly +100–130% (depending on start date) [21] [22] – an astronomical gain fueled by a few catalysts. For comparison, D-Wave (QBTS) and IonQ (IONQ) have also climbed this year (roughly +165% and +48% YTD, respectively [23]), while the S&P 500 is essentially flat. Rigetti’s recent volume has also jumped (TradingView data show daily volume in the hundreds of millions), reflecting frantic buying.

Recent Deals & Technology Milestones

Several headline deals and product news have driven the rally. In late September 2025, Rigetti announced it had booked ~$5.7 million in purchase orders for two Novera on-premises quantum computers [24] [25]. (One order came from a large Asian tech firm and the other from a California AI startup [26].) These Novera units (each 9-qubit and upgradeable) are to be delivered in H1 2026. Simultaneously, Rigetti revealed a 3-year, $5.8M U.S. Air Force contract (via a Quantum Networking collaboration) [27]. Though small in revenue, the Novera and USAF announcements “reinforced investor confidence” and triggered big jumps – Rigetti’s stock rallied ~16% the day the Novera news broke [28] [29].

On the tech side, Rigetti rolled out its new 36-qubit “Cepheus‑1” multi-chip processor in August 2025. Cepheus‑1 (four 9-qubit chiplets) achieves 99.5% two-qubit fidelity [30] and is accessible via Rigetti’s cloud (and soon on Microsoft Azure [31]). Rigetti says this processor “has facilitated its goal of introducing a 100+ qubit system by the end of 2025” [32]. CEO Subodh Kulkarni highlights that Rigetti’s superconducting qubits “leverage… chiplets” to scale to higher qubit counts [33].

Rigetti has also been expanding partnerships: Taiwan’s Quanta Computer invested $35M into Rigetti this year (part of a larger $100M+ collaboration) [34]. In September it signed an MOU with India’s C-DAC to co-develop hybrid quantum-classical systems [35]. And in August 2025 Montana State University installed Rigetti’s first on-campus Novera unit for research [36]. All these deals – though mostly R&D or pilot projects – have kept Rigetti in the headlines and helped sustain the stock momentum. As TechStock² noted, these “headline developments, although modest in revenue, repeatedly fueled double-digit stock jumps… as investors seized on any sign of progress” [37].

Financial Snapshot

Despite the hype, Rigetti’s financials remain in early-stage startup mode. For all of 2024 it recorded just ~$10.8M in revenue (with a net loss of $201M) [38]. In Q2 2025 (ended June), revenue was only $1.8M and the net loss ~$39.7M [39]. Rigetti had no debt and about $571.6M in cash at June 30, 2025 (after a $350M at-the-market stock raise) [40]. This cash cushion means the company can keep burning money on R&D for now, but on a revenue basis it’s negligible (year-to-date 2025 sales total only a few million). One analysis quips that with ~$11–13B market cap the stock trades at a staggering “P/S well over 1000×” [41]. In short, Wall Street is valuing Rigetti on its growth potential rather than its current operations.

Quantum Computing Industry Trends & Peers

Rigetti’s ride is part of a broader quantum stock mania. Pure-play quantum names have seen rocket-like gains in 2025 – e.g. Ts2 reports show IonQ up ~700% YOY, D-Wave ~2,000%, and Rigetti ~4,000% as of mid-October [42]. Media have noted that many of these stocks have surged “4×” or more despite “relatively little revenue” [43]. The optimism is underpinned by big forecasts: McKinsey projects the quantum market could jump from ~$1B today to ~$72B by 2035 [44]. Governments and tech giants are plowing money in (e.g. JPMorgan’s $10B plan, EU and US R&D funding, etc.). But none of the pure-plays are profitable yet.

For context, competitors and tech leaders tell a similar story. IonQ (NYSE: IONQ) has also rallied; its stock near $93 in mid-Oct 2025. In fact, IonQ executed a massive $2.0B stock offering on Oct 10 (16.5M shares at $93 plus warrants) to fund growth [45] – the largest single institutional quantum raise ever. IonQ (a trapped-ion system firm) now has market cap on the order of $25–30B. D-Wave (QBTS) likewise has seen gains on its own news: its Q2 FY2025 revenue was $3.1M (up 42% YoY) with a $167M loss, and it ended the quarter with $819M cash after a $400M raise [46]. D-Wave’s Advantage2 annealing computer rollout and international expansion (e.g. first user conference in Japan) have been highlighted by management [47].

Meanwhile, large tech companies (IBM, Google, Microsoft, etc.) continue quantum R&D: IBM unveiled a 433-qubit “Osprey” processor in 2022 [48] and aims for 4,000+ qubits by 2025 [49]. (IBM’s stock has also recently hit multi-year highs as it invests in AI and quantum [50].) These incumbents have deep pockets and are not reliant on bubble valuations. Rigetti, by contrast, is a pure-play stock completely driven by investor sentiment.

Rigetti’s superconducting quantum approach (left) contrasts with D-Wave’s quantum annealing (right) and IonQ’s trapped-ion systems. All three saw huge share-price gains in 2025. Rigetti’s challenges – tiny revenue and high R&D burn – mirror those of its quantum peers [51] [52].

Analyst Outlook & Expert Commentary

Analysts and pundits are divided on Rigetti. Wall Street is nominally bullish: all the covering analysts rate RGTI a Buy or Strong Buy [53]. However, the average 12-month price target is only ~$20–24 [54] – roughly flat or even lower than current levels, implying significant downside if the stock reverts. (By contrast, only Benchmark’s recent $50 target and B. Riley’s $35 target exceed the mid-$50s price.) As TipRanks notes, some see double-digit upside in related plays, but the consensus target for Rigetti suggests investors should be cautious.

In public comments, CEO Subodh Kulkarni stresses Rigetti is focused on technology milestones: “We are four to five years from real commercial value of quantum computing… at this point it’s all about technology development” [55]. On CNBC, Jim Cramer has oscillated in his view – he once derided RGTI as “the worst quantum play,” then in Aug 2025 said it “could have something… a home run” [56]. Most recently, Cramer warned he “doesn’t know whether [Rigetti] is worth what it’s trading at,” calling it “pure speculation” [57]. Barron’s columnist has likewise cautioned that the rally is a bubble that may “keep inflating until it is tested by fundamentals” [58]. Morgan Stanley’s Joseph Moore goes further: he projects up to ~60% price drops for Rigetti and IonQ if the quantum hype fades [59].

Still, some strategists remain optimistic long-term. As one Bank of America strategist put it, quantum computing may be the “most important technological race” in decades [60], arguing that today’s breakthroughs (and investments) could eventually justify current valuations. In sum, investors are “buying a vision of the future” [61]. Whether that vision pays off – or Rigetti’s parabolic run ends with a crash – remains to be seen.

Analysts’ Price Targets and Projections

Consensus 12-month targets are roughly flat to modestly above today’s levels. Public.com reports 5 analysts on RGTI: 80% rate it Strong Buy and 20% Buy [62], but their average target is only ~$20 [63]. (Zacks/MarketBeat show similar ~19–21 targets.) The most bullish on the street is B. Riley ($35) and Benchmark ($50) [64] – both emphasizing Rigetti’s long-term growth potential. Many others see downside risk. As one report warns, current prices “embed aggressive future growth” that “isn’t yet realized” [65]. Investors should weigh the near-term overheat against multi-year forecasts: for example, McKinsey expects the quantum market to hit ~$72B by 2035 [66] (a figure that underpins some analysts’ faith in stocks like Rigetti). But for now, most analysts treat RGTI as a highly speculative “lottery ticket” – all upside if success comes, but prone to collapse if progress stalls.

Sources: Rigetti filings and press releases; TechStock² and other tech media; Nasdaq/Motley Fool [67]; Insider Monkey [68]; Nasdaq Financial News; CNBC interviews [69] [70]; analyst reports (TipRanks, Zacks, MarketBeat, Public.com); DatacenterDynamics [71]; IBM Newsroom [72] [73]; IonQ investor releases [74]; and other reputable financial news outlets. All figures as of Oct. 14, 2025.

JP Morgan Chase Enters Quantum! Stocks Surge: Rigetti $55, IonQ $80, D-Wave $42 +BBAI Explodes 22%

References

1. ts2.tech, 2. www.insidermonkey.com, 3. ts2.tech, 4. ts2.tech, 5. ts2.tech, 6. ts2.tech, 7. ts2.tech, 8. ts2.tech, 9. ts2.tech, 10. ts2.tech, 11. ts2.tech, 12. ts2.tech, 13. ts2.tech, 14. ts2.tech, 15. www.insidermonkey.com, 16. ts2.tech, 17. www.insidermonkey.com, 18. www.insidermonkey.com, 19. www.insidermonkey.com, 20. www.insidermonkey.com, 21. ts2.tech, 22. ts2.tech, 23. ts2.tech, 24. ts2.tech, 25. www.nasdaq.com, 26. www.nasdaq.com, 27. ts2.tech, 28. www.nasdaq.com, 29. ts2.tech, 30. www.datacenterdynamics.com, 31. www.datacenterdynamics.com, 32. www.datacenterdynamics.com, 33. www.datacenterdynamics.com, 34. ts2.tech, 35. ts2.tech, 36. ts2.tech, 37. ts2.tech, 38. ts2.tech, 39. ts2.tech, 40. ts2.tech, 41. ts2.tech, 42. ts2.tech, 43. ts2.tech, 44. ts2.tech, 45. investors.ionq.com, 46. ts2.tech, 47. ts2.tech, 48. newsroom.ibm.com, 49. newsroom.ibm.com, 50. ts2.tech, 51. ts2.tech, 52. ts2.tech, 53. ts2.tech, 54. ts2.tech, 55. ts2.tech, 56. www.nasdaq.com, 57. ts2.tech, 58. ts2.tech, 59. ts2.tech, 60. ts2.tech, 61. ts2.tech, 62. ts2.tech, 63. ts2.tech, 64. ts2.tech, 65. ts2.tech, 66. ts2.tech, 67. www.nasdaq.com, 68. www.insidermonkey.com, 69. www.nasdaq.com, 70. ts2.tech, 71. www.datacenterdynamics.com, 72. newsroom.ibm.com, 73. newsroom.ibm.com, 74. investors.ionq.com

NuScale’s Stock Skyrockets on 6GW SMR Deal – Is GE Vernova Missing Out?
Previous Story

NuScale’s Stock Skyrockets on 6GW SMR Deal – Is GE Vernova Missing Out?

Dragonfly Energy (DFLI) Patent News Sends Stock Soaring – Will the Rally Last?
Next Story

Dragonfly Energy (DFLI) Patent News Sends Stock Soaring – Will the Rally Last?

Stock Market Today

  • BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Rates Bristol-Myers Squibb at 88%
    October 15, 2025, 3:36 PM EDT. Validea's guru fundamental report flags BRISTOL-MYERS SQUIBB CO (BMY) as the top pick among 22 strategies under the Partha Mohanram P/B Growth Investor model. The model looks for low book-to-market stocks with signs of durable growth, and BMY scores 88%, signaling strong interest from this approach. The stock is described as a large-cap Biotechnology & Drugs name. The scorecard notes key tests such as BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and related metrics mostly PASS, with R&D TO ASSETS and CAPEX TO ASSETS highlighted as favorable. Overall, the framework implies solid fundamentals and attractive valuation, with a high signal from the Mohanram growth criteria for investors tracking factor-based strategies.
  • Bristol-Myers Squibb (BMY) Rated 88% by Validea's Partha Mohanram P/B Growth Strategy
    October 15, 2025, 3:34 PM EDT. Validea's guru analysis for Bristol-Myers Squibb (BMY) shows BMY scoring highest among 22 guru strategies under the P/B Growth Investor model designed by Partha Mohanram. The model looks for low book-to-market stocks with signs of sustained growth; BMY, a large-cap growth stock in the Biotechnology & Drugs sector, earns an 88% rating based on fundamentals and valuation. An 80%+ score signals interest, while 90%+ indicates strong interest. The summary table shows many tests PASS (e.g., BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, etc.), but notes a weakness for RESEARCH AND DEVELOPMENT TO ASSETS (FAILD). The report also provides background on Partha Mohanram and the concept of factor-based stock portfolios.
  • BMY Factor-Based Stock Analysis: Partha Mohanram's P/B Growth Model Rates Bristol-Myers Squibb at 88%
    October 15, 2025, 3:32 PM EDT. Validea's guru-based assessment ranks Bristol-Myers Squibb (BMY) highly under the Partha Mohanram P/B Growth Investor model. Of 22 guru strategies, BMY scores 88%, signaling notable interest from this growth framework. The model targets low book-to-market stocks with indicators of sustained future growth, and BMY is categorized as a large-cap growth stock in the Biotechnology & Drugs sector. The report notes frequent PASS outcomes on key tests (BOOK/MARKET RATIO, ROA, CFO to assets, R&D to assets, etc.) and shows a favorable overall fundamental picture. An emphasis is placed on Mohanram's research on distinguishing winners among low book-to-market stocks, his academic role at the University of Toronto and his chair at the John H. Watson Chair in Value Investing.
  • Bristol-Myers Squibb Co (BMY) Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals Strong Interest
    October 15, 2025, 3:30 PM EDT. Validea's guru fundamental report for Bristol-Myers Squibb Co (BMY) uses the P/B Growth Investor model from Partha Mohanram. The model seeks low book-to-market stocks with sustained growth. BMY is categorized as a large-cap growth stock in the Biotechnology & Drugs sector, and the rating is 88%, implying the strategy has interest (80%) and strong interest above 90%. The accompanying table shows key tests: BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS all passing; R&D TO ASSETS is listed as FAIL. Overall, the framework flags favorable fundamentals and valuation for BMY, though the R&D-to-assets issue may merit closer scrutiny.
  • BMY Factor-Based Stock Analysis: Partha Mohanram's P/B Growth leads with 88%
    October 15, 2025, 3:28 PM EDT. Validea's guru analysis places BRISTOL-MYERS SQUIBB CO (BMY) at the top of its P/B Growth Investor model, a Partha Mohanram framework that seeks low book-to-market names with growth signals. Among 22 guru strategies tracked, BMY earns an 88% score under this model, signaling strong interest from growth-oriented screens. The table notes that key tests such as BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW TO ASSETS, and R&D TO ASSETS show favorable results, while some metrics carry less weight within the strategy. As a large-cap biotech and drugs firm, BMY's fundamentals and valuation align with growth potential per Mohanram's research, though caveats apply to factor-based stock portfolios.
Go toTop